Trial
NCT02985554
Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
University of Chicago
Collaborators
—
Condition
Hematologic Malignancies
Intervention
Nivolumab
Why stopped
Study stopped early due to slow accrual and safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-25